Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

Share Price is delayed by 15 minutes
Get Live Data
41.50    0.00 (0.00%)
Bid:
41.50
Ask:
42.70
Spread: 1.20 (2.892%)
Market Cap: £30.06m
NCYT Live PriceLast checked at - London Stock Exchange

Intraday Novacyt Share Chart

AGM Voting

13 Jun 2022 07:00

RNS Number : 5630O
Novacyt S.A.
13 June 2022
Β 

Β 

Β 

Novacyt S.A.

Β 

("Novacyt", the "Company" or the "Group")

Β 

AGM voting

Β 

Paris, France and Camberley, UK - 13 June 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, will be holding its annual general meeting (AGM) as an open online meeting at 2pm CEST/1pm BST on 21 June 2022. As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary general meetings.

Β 

Under French law, for the meetings to be quorate at the first attempt, at least 20% of the shareholders must vote on the ordinary resolutions and 25% of the shareholders must vote on the extraordinary resolutions. Shareholders are therefore strongly encouraged to submit their proxy votes either by post, email or vote electronically in accordance with the instructions in the notice convening the meeting, copies of which are available in the General Meetings section on the Company's website at www.novacyt.com/investors.

Β 

Following registration and proof of shareholding, shareholders will be able to virtually attend the AGM and vote online during the meeting if they wish. Following the meeting, a recording of the AGM will be available on the Company's website at www.novacyt.com/investors. Shareholders who have already voted (through a proxy, using the AGM or Votaccess portals) will be allowed to attend the AGM but will not be able to vote twice.

Β 

- End -

Β 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

Β 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

Β 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

Β 

Allegra Finance (French Listing Sponsor)

RΓ©mi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

Β 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / Alex.Shaw@fticonsulting.com Β 

Β 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com Β 

Β 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company supplies an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

Β 

For more information, please refer to the website: www.novacyt.comΒ 

Β 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word β€œReach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
NRABKBBBDBKBKAD
Date   Source Headline
20th Aug 20217:00 amRNSNotice of AGM
18th Aug 20217:00 amRNSHalf Year Update
5th Aug 20217:00 amRNSNotice of investor meeting
2nd Aug 20211:30 pmRNSTotal Voting Rights
29th Jul 20217:00 amRNSDavid Allmond to be CEO, Graham Mullis to retire
6th Jul 20212:40 pmRNSDirector/PDMR Shareholding
1st Jul 20212:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Jun 20217:00 amRNSPublication of Annual Report
29th Jun 20217:00 amRNSExpansion of PathFlow COVID-19 LFT portfolio
22nd Jun 20217:00 amRNSFull year 2020 results and update on strategy
18th Jun 20217:00 amRNSUpdate on Notice of 2020 Full Year Results
3rd Jun 20217:00 amRNSLaunch of two new PCR COVID-19 assays
1st Jun 20212:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20217:00 amRNSLaunch of VersaLab Portable
21st May 20217:00 amRNSDHSC Dispute Update
17th May 20217:00 amRNSInclusion of SNPsig in the NHS England Framework
4th May 20211:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSNovacyt donates 1 million COVID-19 tests to UNICEF
23rd Apr 20217:00 amRNSR&D and UK operational update
22nd Apr 20217:00 amRNSNotice of Results
9th Apr 202112:30 pmRNSTrading Update
1st Apr 20211:40 pmRNSTotal Voting Rights
24th Mar 20217:00 amRNSLaunch of VariPLEX CE-Mark test
17th Mar 20217:11 amRNSLaunch of mobile processing laboratories
15th Mar 20214:45 pmRNSHoldings in Company
15th Mar 202111:30 amRNSHolding(s) in Company
12th Mar 202111:00 amRNSHoldings in Company
1st Mar 20212:30 pmRNSLiquidity Agreement and Total Voting Rights
24th Feb 20216:30 pmRNSCorrection: Research and Development Update
24th Feb 20217:00 amRNSResearch and Development Update
2nd Feb 20217:00 amRNSLaunch of PCR assay portfolio
1st Feb 202112:30 pmRNSTotal Voting Rights
29th Jan 20217:00 amRNSFull Year 2020 Trading Update
26th Jan 20215:30 pmRNSHolding(s) in Company
13th Jan 202112:30 pmRNSHoldings in Company
5th Jan 20217:00 amRNSExecutive Management and Proposed Board Changes
4th Jan 20212:15 pmRNSLiquidity Agreement and Total Voting Rights
21st Dec 20207:00 amRNSNew COVID-19 variant
14th Dec 20207:00 amRNSTests for new strains of COVID-19 and avian flu
2nd Dec 20201:15 pmRNSHolding(s) in Company
1st Dec 20202:15 pmRNSLiquidity Agreement and Total Voting Rights
18th Nov 20206:20 pmRNSDirector/PDMR Shareholding
16th Nov 20207:00 amRNSR&D Update
13th Nov 20206:05 pmRNSDirector/PDMR Shareholding
13th Nov 20207:00 amRNSDirector/PDMR Shareholding
12th Nov 20207:00 amRNSDirector/PDMR Shareholding
11th Nov 202011:05 amRNSDirector/PDMR Shareholding
2nd Nov 20201:00 pmRNSLiquidity Agreement and Total Voting Rights
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.